A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
about
The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort studyPneumococcal vaccine for preventing Streptococcus pneumoniae infection in HIV-infected individualsVaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalitiesRevised adult immunization guideline recommended by the korean society of infectious diseases, 2014.The role of vaccination in preventing pneumococcal disease in adultsPersistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program[Vaccination against pneumococci and influenza. How good is the evidence?].Contribution of vaccines to our understanding of pneumococcal disease.High rate of pneumococcal bacteremia in a prospective cohort of older children and adults in an area of high HIV prevalence in rural western Kenya.The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review.Pneumococcal Vaccination Strategies. An Update and Perspective.Incomplete recovery of pneumococcal CD4 T cell immunity after initiation of antiretroviral therapy in HIV-infected malawian adults.Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi.Vaccination in HIV-infected adults.Impaired CD4 T cell memory response to Streptococcus pneumoniae precedes CD4 T cell depletion in HIV-infected Malawian adultsA randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection.The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Etiology and Incidence of viral and bacterial acute respiratory illness among older children and adults in rural western Kenya, 2007-2010.Genomic pneumococcal load and CSF cytokines are not related to outcome in Malawian adults with meningitis.Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.Regulation of naturally acquired mucosal immunity to Streptococcus pneumoniae in healthy Malawian adults and children.Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?High mortality amongst adolescents and adults with bacterial meningitis in sub-Saharan Africa: an analysis of 715 cases from MalawiSerotype distribution in non-bacteremic pneumococcal pneumonia: association with disease severity and implications for pneumococcal conjugate vaccinesEpidemiology of severe acute respiratory illness (SARI) among adults and children aged ≥5 years in a high HIV-prevalence setting, 2009-2012.A reduction in adult blood stream infection and case fatality at a large African hospital following antiretroviral therapy roll-out.Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.Minimum incidence of adult invasive pneumococcal disease in Blantyre, Malawi an urban african setting: a hospital based prospective cohort studyUpdate in pulmonary infections 2010.Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial.Community-acquired pneumonia: pneumococcal vaccine.Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV).Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal VaccinationSafety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.
P2860
Q21261827-1EF04B80-FCCE-4111-86DE-4487E7488B05Q24186767-5E09C1DE-5E11-47F1-BB05-49A6989906D0Q26796420-1DCDFCE3-0E07-4129-A4B4-9A7045B382DFQ26821898-FBDF7CDE-06EF-42BB-B3B9-B9E858CF64DEQ28396749-6F1E625A-D95E-4C7A-96EB-8E39E11EDFD3Q28742203-CD07B9FB-E462-4365-96D2-6B9FFF129B7DQ30395309-020ECD76-48E1-4373-9719-96949382AAB5Q30406750-BFD8B190-F13E-4F80-A1A5-1B0661A2B2BAQ33614281-8FEF38A2-131D-4588-8706-19BBBCFD0222Q33741026-71A2F5D3-11EA-4A79-B31E-20EC55EC19A2Q33772409-1A2867C2-0081-4E80-9B45-1AEB111B19B3Q33800556-F20702A7-E22C-4C48-929C-0885D0E123D6Q33851271-03906DCA-B1F4-45C2-829E-F617FDE0E19FQ33980764-BEE4AAAB-DA0A-4591-81B8-10F2B7C0AD69Q34043394-C7460A56-CA5F-4C4B-9485-1E287503508EQ34101331-A20CBC41-C451-4B64-8BEA-A0C76B89C0E3Q34196888-64C6445D-7B46-4F1A-9129-8247126C7B6CQ34311579-50ACE2F2-BBE1-49F2-9504-85859105B905Q34364783-02EBBAA1-C19C-42AC-9956-A00D46320692Q34390072-776D2BCD-765E-4DF8-9517-457D2AAC3DCFQ34399272-449EFD97-022D-4774-BE2E-E5906CDC588CQ34406177-D4482B4F-EE6F-49EA-A550-A00D99E6F9FFQ34452479-911CC848-5EC0-462D-BB14-B158DB88D35FQ34531875-AE7F9CB0-0A34-4736-B4A2-801429E98C71Q34798448-AC066466-1FCB-45D6-8A1C-6625B40142C1Q34874445-E25E6521-89AB-4A76-BE88-5AD20D5632C0Q34979620-F67307DD-3D51-4212-B6BB-DCFF327811C1Q35112120-20AB2213-B40A-429F-BFE7-1DAD7F91792BQ35124323-A9FBB4F3-929F-4207-B194-F1B70BC375C3Q35134469-ECC73F37-6487-403B-9EEC-95E5A3615CC5Q35622117-25CC06DA-47D6-4EDE-B3DD-8E148839B8F2Q35651036-A197A748-E37F-4E61-886D-9907A4E59825Q35692215-2CBF3520-E7A4-4784-B8F0-08E5FC282C77Q35753485-D6D6E5B6-A669-494F-A103-67E5ABD63C96Q35860515-D046BE9F-52B1-466E-A1F2-8E58500983BAQ35907519-FC7526EA-EA3C-4708-BD71-B574F8AEAE9EQ35919614-968C14A0-74A4-4268-99D0-75CB4086BB56Q35988851-C5CD71B0-04DF-4E08-BB6F-57C1EF87B4A0Q36009704-C5686D4F-2C6E-4FC5-9E23-F46D1F9118D3Q36040140-BB03029D-F3FF-407F-A429-3A810906053E
P2860
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
@ast
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
@en
type
label
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
@ast
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
@en
prefLabel
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
@ast
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
@en
P2093
P2860
P50
P356
P1476
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
@en
P2093
Eduard E Zijlstra
Gershom Mwafulirwa
Herbert Longwe
Martin Mwaiponya
Sarah A White
Thandie Mwalukomo
P2860
P304
P356
10.1056/NEJMOA0903029
P407
P577
2010-03-01T00:00:00Z